Blog Posts
June 16, 2023

Exciting Trial Data Reveals AstraZeneca's Lung Cancer Therapy, Tagrisso, Reduces Risk of Death by Over 50% in Early-Stage Patients

Blog Posts
June 16, 2023

Exciting Trial Data Reveals AstraZeneca's Lung Cancer Therapy, Tagrisso, Reduces Risk of Death by Over 50% in Early-Stage Patients

Author
Neneh Vannitamby, MD
Medical Writer

AstraZeneca's groundbreaking lung cancer therapy, Tagrisso, has demonstrated remarkable results in a clinical trial, decreasing the risk of death by more than half in patients diagnosed early enough to have their tumor surgically removed.

Tagrisso, already a useful asset for the Anglo-Swedish drugmaker, generated $5.4 billion in revenue last year. With regulatory approvals in various regions for non-small cell lung cancer (NSCLC) patients with EGFR gene mutations, the drug's potential continues to grow.

AstraZeneca's groundbreaking lung cancer therapy, Tagrisso, has demonstrated remarkable results in a clinical trial, decreasing the risk of death by more than half in patients diagnosed early enough to have their tumor surgically removed.

Tagrisso, already a useful asset for the Anglo-Swedish drugmaker, generated $5.4 billion in revenue last year. With regulatory approvals in various regions for non-small cell lung cancer (NSCLC) patients with EGFR gene mutations, the drug's potential continues to grow.

Presented at the American Society of Clinical Oncology (ASCO) 2023 meeting, the trial data establishes Tagrisso as the leading treatment for EGFR-mutated lung cancer. Susan Galbraith, Executive VP of Oncology R&D at AstraZeneca, hailed the findings as a significant step forward.

During the ADAURA trial, involving 682 patients, Tagrisso was compared to a placebo in earlier-stageNSCLC patients who had undergone surgery to remove their primary tumor. Despite surgical intervention and supplementary chemotherapy, most of these patients experience cancer recurrence. The trial aimed to determine whether Tagrisso could prevent cancer from returning.

The data revealed that Tagrisso reduced the risk of death by an astounding 51% compared to the placebo, a truly dramatic improvement. Moreover, the trial showed that approximately 88% of patients treated with Tagrisso were still alive after five years, compared to 78% on the placebo. 

Dave Fredrickson, Executive VicePresident of Oncology at AstraZeneca, expressed enthusiasm about these findings, noting that Tagrisso is currently the only drug, aside from chemotherapy, proven to extend the lives of patients with EGFR-mutated lung cancer. Fredrickson emphasized that a significant proportion of eligible patients are not yet being prescribed Tagrisso, and the hope is that these compelling results will help close that gap.

In addition to this success, AstraZeneca is also anticipated to release details later this year regarding the impact of combining Tagrisso with chemotherapy in patients with advancedEGFR-mutated lung cancer. The company's dedication to improving outcomes for lung cancer patients continues to drive progress in the field.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.